{
    "id": "dbpedia_1597_0",
    "rank": 89,
    "data": {
        "url": "https://www.inotivco.com/models/cacna1c-rats",
        "read_more_link": "",
        "language": "en",
        "title": "Cacna1c rats",
        "top_image": "https://www.inotiv.com/hubfs/resources/model-images/Envigo-Cacna1c-KO-rat.jpg",
        "meta_img": "https://www.inotiv.com/hubfs/resources/model-images/Envigo-Cacna1c-KO-rat.jpg",
        "images": [
            "https://no-cache.hubspot.com/cta/default/212573/47debb49-88c0-47ff-b7e8-3c8fa70cf799.png",
            "https://www.inotiv.com/hubfs/2022%20Website/icon-elements-bottom.png",
            "https://www.inotiv.com/hs-fs/hubfs/images/logo/Inotiv-Frost-and-Sullivan-2022-Award.png?width=150&height=138&name=Inotiv-Frost-and-Sullivan-2022-Award.png",
            "https://px.ads.linkedin.com/collect/?pid=5039554&fmt=gif"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://www.inotiv.com/models/cacna1c-rats",
        "text": "Siddique AB, Kilgore PCSR, Tajmim A, Singh SS, Meyer SA, Jois SD, Cvek U, Trutschl M, Sayed KAE., (-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer, Nutrients. 2020 Jun 11;12(6):1749. doi: 10.3390/nu12061749.\n\nJiménez-Mora E, Gallego B, Díaz-Gago S, Lasa M, Baquero P, Chiloeches A., (V600E)BRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells, Int J Mol Sci. 2021 Jun 3;22(11):6033. doi: 10.3390/ijms22116033.\n\nMasoodi, K. Z., Ramos Garcia, R., Pascal, L. E., Wang, Y., Ma, H. M., O'Malley, K., . . . Wang, Z. (2013)., 5alpha-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models., Endocrinology, 154(7), 2296-2307. doi:10.1210/en.2012-2077 [doi]\n\nYang, Hailing; Shu, Zhang; Jiang, Yongying; Mao, Weiqun; Pang, Lan; Redwood, Abena; Jeter-Jones, Sabrina L; Jennings, Nicholas B; Ornelas, Argentina; Zhou, Jinhua; Rodriguez-Aguayo, Cristian; Bartholomeusz, Geoffrey; Iles, LaKesla R; Zacharias, Niki M; Millward, Steven W; Lopez-Berestein, Gabriel; Le, Xiao-Feng; Ahmed, Ahmed A; Piwnica-Worms, Helen; Sood, Anil K; Bast, Robert C; Lu, Zhen, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers, Clinical cancer research : an official journal of the American Association for Cancer Research Vol.25, 2019\n\nMarayati R, Bownes LV, Stafman LL, Williams AP, Quinn CH, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA., 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts, Transl Oncol. 2021 Jan;14(1):100893. doi: 10.1016/j.tranon.2020.100893. Epub 2020 Sep 30.\n\nMarayati R, Bownes LV, Stafman LL, Williams AP, Quinn CH, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA., 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts, Transl Oncol. 2021 Jan;14(1):100893. doi: 10.1016/j.tranon.2020.100893. Epub 2020 Sep 30.\n\nDeng, Y., Wang, Z., Zhang, F., Qiao, M., Yan, Z., Wei, Q., . . . Zhang, J. (2016), A blockade of IGF signaling sensitizes human ovarian cancer cells to the anthelmintic niclosamide-induced anti-proliferative and anticancer activities, Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 39(3), 871-888. doi:10.1159/000447797 [doi]\n\nKuznik NC, Solozobova V, Lee II, Jung N, Yang L, Nienhaus K, Ntim EA, Rottenberg JT, Muhle-Goll C, Kumar AR, Peravali R, Gräßle S, Gourain V, Deville C, Cato L, Neeb A, Dilger M, Cramer von Clausbruch CA, Weiss C, Kieffer B, Nienhaus GU, Brown M, Bräse S, Cato ACB., A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway, iScience. 2022 Mar 31;25(5):104175. doi: 10.1016/j.isci.2022.104175. eCollection 2022 May 20.\n\nZhao Y, Wang C, Goel A., A combined treatment with melatonin and andrographis promotes autophagy and anticancer activity in colorectal cancer, Carcinogenesis. 2022 Apr 25;43(3):217-230. doi: 10.1093/carcin/bgac008.\n\nLuderer, M. J., Muz, B., de la Puente, P., Chavalmane, S., Kapoor, V., Marcelo, R., . . . Azab, A. K. (2016), A hypoxia-targeted boron neutron capture therapy agent for the treatment of glioma., Pharmaceutical Research, 33(10), 2530-2539. doi:10.1007/s11095-016-1977-2 [doi]\n\nTian Q, Zhang P, Wang Y, Si Y, Yin D, Weber CR, Fishel ML, Pollok KE, Qiu B, Xiao F, Chong AS., A novel triptolide analog downregulates NF-kB and induces mitochondrial apoptosis pathways in human pancreatic cancer., Elife. 2023 Oct 25;12. pii: e85862. doi: 10.7554/eLife.85862. [Epub ahead of print]\n\nShivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, Kim J, Doan B, Riddle P, Tushir-Singh J., A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors, Cell Rep. 2021 Nov 2;37(5):109953. doi: 10.1016/j.celrep.2021.109953.\n\nHight, M. R., Cheung, Y. Y., Nickels, M. L., Dawson, E. S., Zhao, P., Saleh, S., . . . Manning, H. C. (2014)., A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(8), 2126-2135. doi:10.1158/1078-0432.CCR-13-2444 [doi]\n\nDey, J., Kerwin, W. S., Grenley, M. O., Casalini, J. R., Tretyak, I., Ditzler, S. H., . . . Klinghoffer, R. A. (2016), A platform for rapid, quantitative assessment of multiple drug combinations simultaneously in solid tumors in vivo., PloS One, 11(6), e0158617. doi:10.1371/journal.pone.0158617 [doi]\n\nGreen, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., . . . Press, O. W. (2014), A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies., Cancer Research, 74(4), 1179-1189. doi:10.1158/0008-5472.CAN-13-1589 [doi]\n\nYang, Lu; Li, Yun; Bhattacharya, Arup; Zhang, Yuesheng;, A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer., Science translational medicine Vol.11, 2019\n\nNeiveyans, Madeline; Melhem, Rana; Arnoult, Christophe; Bourquard, Thomas; Jarlier, Marta; Busson, Muriel; Laroche, Adrien; Cerutti, Martine; PugniĂ¨re, Martine; Ternant, David; Gaborit, NadĂ¨ge; ChardĂ¨s, Thierry; Poupon, Anne; Gouilleux-Gruart, ValĂŠrie; PĂ¨legrin, Andre; Poul, Marie-Alix;, A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions, mAbs Vol.11, 2019\n\nSantich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK., A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy, Clin Cancer Res. 2020 Sep 21. doi: 10.1158/1078-0432.CCR-20-2150. Online ahead of print.\n\nSantich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK., A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy, Clin Cancer Res. 2021 Jan 15;27(2):532-541. doi: 10.1158/1078-0432.CCR-20-2150. Epub 2020 Sep 21.\n\nPattarawat P, Hunt JT, Poloway J, Archibald CJ, Wang HR., A triple combination gemcitabine?+?romidepsin?+?cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis, Cancer Chemother Pharmacol. 2021 Sep;88(3):415-425. doi: 10.1007/s00280-021-04298-y. Epub 2021 May 27.\n\nRoy, L. D., Dillon, L. M., Zhou, R., Moore, L. J., Livasy, C., El-Khoury, J. M., . . . Mukherjee, P. (2017)., A tumor specific antibody to aid breast cancer screening in women with dense breast tissue., Genes & Cancer, 8(3-4), 536-549. doi:10.18632/genesandcancer.134 [doi]\n\nKim, S. S., Rait, A., Kim, E., Pirollo, K. F., & Chang, E. H. (2015)., A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme., Nanomedicine : Nanotechnology, Biology, and Medicine, 11(2), 301-311. doi:10.1016/j.nano.2014.09.005 [doi]\n\nFormisano, Luigi; Lu, Yao; Servetto, Alberto; Hanker, Ariella B; Jansen, Valerie M; Bauer, Joshua A; Sudhan, Dhivya R; Guerrero-Zotano, Angel L; Croessmann, Sarah; Guo, Yan; Ericsson, Paula Gonzalez; Lee, Kyung-Min; Nixon, Mellissa J; Schwarz, Luis J; Sanders, Melinda E; Dugger, Teresa C; Cruz, Marcelo Rocha; Behdad, Amir; Cristofanilli, Massimo; Bardia, Aditya; OShaughnessy, Joyce; Nagy, Rebecca J; Lanman, Richard B; Solovieff, Nadia; He, Wei; Miller, Michelle; Su, Fei; Shyr, Yu; Mayer, Ingrid A; Balko, Justin M; Arteaga, Carlos L;, Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer., Nature communications Vol.10, 2019\n\nLi M, Li J, Guo X, Pan H, Zhou Q., Absence of HTATIP2 Expression in A549 Lung Adenocarcinoma Cells Promotes Tumor Plasticity in Response to Hypoxic Stress, Cancers (Basel). 2020 Jun 11;12(6):1538. doi: 10.3390/cancers12061538.\n\nTansi, F. L., Ruger, R., Bohm, C., Steiniger, F., Kontermann, R. E., Teichgraeber, U. K., . . . Hilger, I. (2017)., Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously., Acta Biomaterialia, 54, 281-293. doi:S1742-7061(17)30203-9 [pii]\n\nYoung, N. R., Soneru, C., Liu, J., Grushko, T. A., Hardeman, A., Olopade, O. I., . . . Cohen, E. E. (2015)., Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo., Targeted Oncology, 10(4), 501-508. doi:10.1007/s11523-014-0353-6 [doi]\n\nZiegler, J., Bastian, A., Lerner, M., Bailey-Downs, L., Saunders, D., Smith, N., . . . Towner, R. A. (2017)., AG488 as a therapy against gliomas., Oncotarget, 8(42), 71833-71844. doi:10.18632/oncotarget.18284 [doi]\n\nGomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, Schild T, Broekaert D, Ahmed A, Planque M, Elia I, Han J, Kinzig C, Mullarky E, Mutvei AP, Asara J, de Cabo R, Cantley LC, Dephoure N, Fendt SM, Blenis J., Age-induced accumulation of methylmalonic acid promotes tumour progression, Nature. 2020 Sep;585(7824):283-287. doi: 10.1038/s41586-020-2630-0. Epub 2020 Aug 19.\n\nDunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K., AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors, Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14.\n\nSun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, Carroll CL, Chang Q, Feng N, Gao G, Gera S, Giuliani V, Huang JK, Jiang Y, Kang Z, Kovacs JJ, Liu CY, Lopez AM, Ma X, Mandal PK, McAfoos T, Miller MA, Mullinax RA, Peoples M, Ramamoorthy V, Seth S, Spencer ND, Suzuki E, Williams CC, Yu SS, Zuniga AM, Draetta GF, Marszalek JR, Heffernan TP, Kohl NE, Jones P., Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib, Cancer Res. 2020 Nov 1;80(21):4840-4853. doi: 10.1158/0008-5472.CAN-20-1634. Epub 2020 Sep 14.\n\nZhang, R., Pan, D., Cai, X., Yang, X., Senpan, A., Allen, J. S., . . . Wang, L. V. (2015), alphaVbeta3-targeted copper nanoparticles incorporating an sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment., Theranostics, 5(2), 124-133. doi:10.7150/thno.10014 [doi]\n\nBush, T. L., Payton, M., Heller, S., Chung, G., Hanestad, K., Rottman, J. B., . . . Radinsky, R. (2013), AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models, Molecular Cancer Therapeutics, 12(11), 2356-2366. doi:10.1158/1535-7163.MCT-12-1178 [doi]\n\nAsundi, J., Crocker, L., Tremayne, J., Chang, P., Sakanaka, C., Tanguay, J., . . . Firestein, R. (2015), An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(14), 3252-3262. doi:10.1158/1078-0432.CCR-15-0156 [doi]\n\nCitron, F., Armenia, J., Franchin, G., Polesel, J., Talamini, R., D'Andrea, S., . . . Baldassarre, G. (2017), An integrated approach identifies mediators of local recurrence in head and neck squamous carcinoma, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(14), 3769-3780. doi:10.1158/1078-0432.CCR-16-2814 [doi]\n\nZhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., . . . Ji, P. (2017)., Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)., Oncotarget, 8(8), 12968-12982. doi:10.18632/oncotarget.14673 [doi]\n\nMiles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017)., Anthrax toxin receptor 1 is the cellular receptor for seneca valley virus., The Journal of Clinical Investigation, 127(8), 2957-2967. doi:10.1172/JCI93472 [doi]\n\nMoody, G., Belmontes, B., Masterman, S., Wang, W., King, C., Murawsky, C., . . . Beltran, P. J. (2016)., Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo, International Journal of Cancer, 139(6), 1340-1349. doi:10.1002/ijc.30180 [doi]\n\nTabernero, J., Chawla, S. P., Kindler, H., Reckamp, K., Chiorean, E. G., Azad, N. S., . . . Baselga, J. (2015)., Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab., argeted Oncology, 10(1), 65-76. doi:10.1007/s11523-014-0315-z [doi]\n\nZhang S, Zhao L, Guo M, Liu P, Li S, Xie W, Tian AL, Pol JG, Chen H, Pan H, Mao M, Li Y, Zitvogel L, Jin Y, Kepp O, Kroemer G., Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses., J Immunother Cancer. 2023 Jul;11(7). pii: e006785. doi: 10.1136/jitc-2023-006785.\n\nLi, X., Wu, J. B., Chung, L. W., & Huang, W. C. (2015)., Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations., Oncotarget, 6(38), 41018-41032. doi:10.18632/oncotarget.5879 [doi]\n\nYan, H., Kapoor, V., Nguyen, K., Akers, W. J., Li, H., Scott, J., . . . Hallahan, D. (2016)., Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers., Oncotarget, 7(28), 43352-43362. doi:10.18632/oncotarget.9713 [doi]\n\nJuzeniene, A., Bernoulli, J., Suominen, M., Halleen, J., & Larsen, R. H. (2018)., Antitumor activity of novel bone-seeking, alpha-emitting (224)ra-solution in a breast cancer skeletal metastases model, Anticancer Research, 38(4), 1947-1955. doi:38/4/1947 [pii]\n\nBrignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, Corrias MV, Astigiano S, Cilli M, Loo D, Bonvini E, Pastorino F, Ponzoni M., Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma., J Immunother Cancer. 2023 Sep;11(9). pii: e007174. doi: 10.1136/jitc-2023-007174.\n\nBen-Eltriki M, Deb S, Shankar G, Meckling G, Hassona M, Yamazaki T, Fazli L, Chin MY, Tomlinson Guns ES., Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer, Medicines (Basel). 2021 Jun 4;8(6):28. doi: 10.3390/medicines8060028.\n\nHallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG., Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor, Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.\n\nSu W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N., ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1, Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24.\n\nSmith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin JH, Mistry M, Rao NS, Denis LJ, Gupta S., ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models, Mol Cancer Ther. 2021 Aug;20(8):1327-1337. doi: 10.1158/1535-7163.MCT-20-0565. Epub 2021 May 27.\n\nZumwalt, T. J., Wodarz, D., Komarova, N. L., Toden, S., Turner, J., Cardenas, J., . . . Goel, A. (2017)., Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells., Cancer Prevention Research (Philadelphia, Pa.), 10(3), 208-218. doi:10.1158/1940-6207.CAPR-16-0175 [doi]\n\nGreen, D. J., Shadman, M., Jones, J. C., Frayo, S. L., Kenoyer, A. L., Hylarides, M. D., . . . Press, O. W. (2015)., Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, Blood, 125(13), 2111-2119. doi:10.1182/blood-2014-11-612770 [doi]\n\nDavis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM., ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer, BMC Cancer. 2022 Oct 29;22(1):1107. doi: 10.1186/s12885-022-10084-7.\n\nDi Francesco M, Pastorino F, Ferreira M, Fragassi A, Di Francesco V, Palange AL, Celia C, Di Marzio L, Cilli M, Bensa V, Ponzoni M, Decuzzi P., Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma, Pharmacol Res. 2022 Dec 28;188:106639. doi: 10.1016/j.phrs.2022.106639. Online ahead of print.\n\nDi Francesco M, Pastorino F, Ferreira M, Fragassi A, Di Francesco V, Palange AL, Celia C, Di Marzio L, Cilli M, Bensa V, Ponzoni M, Decuzzi P., Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma., Pharmacol Res. 2023 Feb;188:106639. doi: 10.1016/j.phrs.2022.106639. Epub 2022 Dec 28.\n\nJohnson SS, Liu D, Ewald JT, Robles-Planells C, Bayanbold K, Wels BR, Solst SR, O'Dorisio MS, Allen BG, Menda Y, Spitz DR, Fath MA., Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer., bioRxiv. 2023 May 9. pii: 2023.05.07.539772. doi: 10.1101/2023.05.07.539772.\n\nYeo, S. K., Wen, J., Chen, S., & Guan, J. L. (2016)., Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfbeta/Smad signaling, Cancer Research, 76(11), 3397-3410. doi:10.1158/0008-5472.CAN-15-2946 [doi]\n\nWang Y, Xie W, Humeau J, Chen G, Liu P, Pol J, Zhang Z, Kepp O, Kroemer G., Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy, J Immunother Cancer. 2020 Mar;8(1):e000462. doi: 10.1136/jitc-2019-000462.\n\nLoddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P., . . . Brooks, A. N. (2013)., AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo., Molecular Cancer Therapeutics, 12(9), 1715-1727. doi:10.1158/1535-7163.MCT-12-1174 [doi]\n\nFok, Jacqueline H L; Ramos-Montoya, Antonio; Vazquez-Chantada, Mercedes; Wijnhoven, Paul W G; Follia, Valeria; James, Neil; Farrington, Paul M; Karmokar, Ankur; Willis, Sophie E; Cairns, Jonathan; NikkilĂ¤, Jenni; Beattie, David; Lamont, Gillian M; Finlay, M Raymond V; Wilson, Joanne; Smith, Aaron; OConnor, Lenka Oplustil; Ling, Stephanie; Fawell, Stephen E; OConnor, Mark J; Hollingsworth, Simon J; Dean, Emma; Goldberg, Frederick W; Davies, Barry R; Cadogan, Elaine B;, AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity., Nature communications Vol.10, 2019\n\nRello-Varona, Santi; Fuentes-Guirado, Miriam; LĂłpez-Alemany, Roser; Contreras-PĂŠrez, Aida; Mulet-Margalef, NĂşria; GarcĂ­a-MonclĂşs, Silvia; Tirado, Oscar M; GarcĂ­a Del Muro, Xavier, Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas, Scientific reports Vol.9, 2019\n\nSan Millan, C., Soldevilla, B., Martin, P., Gil-Calderon, B., Compte, M., Perez-Sacristan, B., . . . Dominguez, G. (2015), Beta-cryptoxanthin synergistically enhances the antitumoral activity of oxaliplatin through DeltaNP73 negative regulation in colon cancer, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(19), 4398-4409. doi:10.1158/1078-0432.CCR-14-2027 [doi]\n\nJansen, M. H., Lagerweij, T., Sewing, A. C., Vugts, D. J., van Vuurden, D. G., Molthoff, C. F., . . . Hulleman, E. (2016)., Bevacizumab targeting diffuse intrinsic pontine glioma: Results of 89Zr-bevacizumab PET imaging in brain tumor models., Molecular Cancer Therapeutics, 15(9), 2166-2174. doi:10.1158/1535-7163.MCT-15-0558 [doi]\n\nSingh AK, Dadey DY, Rau MJ, Fitzpatrick J, Shah HK, Saikia M, Townsend R, Thotala D, Hallahan DE, Kapoor V., Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy., Biomed Pharmacother. 2023 Oct;166:115341. doi: 10.1016/j.biopha.2023.115341. Epub 2023 Aug 23.\n\nZhang, Y., Chen, X., Qiao, M., Zhang, B. Q., Wang, N., Zhang, Z., . . . Zhang, H. (2014)., Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells., Oncology Reports, 32(3), 1013-1020. doi:10.3892/or.2014.3308 [doi]\n\nChiou AE, Liu C, Moreno-Jiménez I, Tang T, Wagermaier W, Dean MN, Fischbach C, Fratzl P., Breast cancer-secreted factors perturb murine bone growth in regions prone to metastasis, Sci Adv. 2021 Mar 17;7(12):eabf2283. doi: 10.1126/sciadv.abf2283. Print 2021 Mar.\n\nBai L, Li X, Yang Y, Zhao R, White EZ, Danaher A, Bowen NJ, Hinton CV, Cook N, Li D, Wu AY, Qui M, Du Y, Fu H, Kucuk O, Wu D., Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models., Transl Oncol. 2023 Aug;34:101707. doi: 10.1016/j.tranon.2023.101707. Epub 2023 Jun 2.\n\nPatel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, Arthur P, Duke LC, York SB, Bagde A, Meckes DG Jr, Singh M., Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models, Int J Pharm. 2021 Sep 25;607:120943. doi: 10.1016/j.ijpharm.2021.120943. Epub 2021 Jul 27.\n\nBort, A., Spinola, E., Rodriguez-Henche, N., & Diaz-Laviada, I. (2017)., Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation, Oncotarget, 8(50), 87684-87698. doi:10.18632/oncotarget.21196 [doi]\n\nKim, H. S., Masko, E. M., Poulton, S. L., Kennedy, K. M., Pizzo, S. V., Dewhirst, M. W., & Freedland, S. J. (2012)., Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer., BJU International, 110(7), 1062-1069. doi:10.1111/j.1464-410X.2012.10971.x [doi]\n\nMoon, Henry H; Clines, Katrina L; Cooks, Mark A; Cialek, Charlotte A; Esvelt, Marian A; Clines, Gregory A;, Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone, Endocrinology Vol.160, 2019\n\nLi, H., Xie, N., Gleave, M. E., & Dong, X. (2015, Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression., Oncotarget, 6(24), 20474-20484. doi:4105 [pii]\n\nAssimon, Victoria A; Tang, Yangzhong; Vargas, Jesse D; Lee, Grace J; Wu, Zhi Yong; Lou, Kenny; Yao, Bing; Menon, Mary-Kamala; Pios, Ariel; Perez, Kristy C; Madriaga, Antonett; Buchowiecki, Peter K; Rolfe, Mark; Shawver, Laura; Jiao, Xianyun; Le Moigne, Ronan; Zhou, Han-Jie; Anderson, Daniel J;, CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity. ACS chemical biology, ACS chemical biology Vol.14, 2019\n\nCasagrande, Naike; Borghese, Cinzia; Visser, Lydia; Mongiat, Maurizio; Colombatti, Alfonso; Aldinucci, Donatella, CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth., Haematologica Vol.104, 2019\n\nDomínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, Zapata JM., CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110, J Hematol Oncol. 2020 Apr 7;13(1):32. doi: 10.1186/s13045-020-00865-7.\n\nPuigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M., CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models, J Immunother Cancer. 2021 Jul;9(7):e002644. doi: 10.1136/jitc-2021-002644.\n\nHernandez, R., Sun, H., England, C. G., Valdovinos, H. F., Ehlerding, E. B., Barnhart, T. E., . . . Cai, W. (2016), CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody., Theranostics, 6(11), 1918-1933. doi:10.7150/thno.15568 [doi]\n\nMcKnight BN, Kim S, Boerner JL, Viola NT., Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer, Breast Cancer Res. 2020 Apr 15;22(1):37. doi: 10.1186/s13058-020-01270-1.\n\nSmith, M. C., Mader, M. M., Cook, J. A., Iversen, P., Ajamie, R., Perkins, E., . . . Wacheck, V. (2016)., Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth., Molecular Cancer Therapeutics, 15(10), 2344-2356. doi:1535-7163.MCT-15-0996 [pii]\n\nFritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR., Characterization of the novel and specific PI3K? inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials, Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.\n\nBolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G., Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system, Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2.\n\nWeitzenfeld, P., Kossover, O., Korner, C., Meshel, T., Wiemann, S., Seliktar, D., . . . Ben-Baruch, A. (2016)., Chemokine axes in breast cancer: Factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors., Journal of Leukocyte Biology, 99(6), 1009-1025. doi:10.1189/jlb.3MA0815-373R [doi]\n\nHain, Brian A; Xu, Haifang; Wilcox, Jenna R; Mutua, Daniel; Waning, David L;, Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia., JCSM rapid communications Vol.2,\n\nRusso M, Panini N, Fabbrizio P, Formenti L, Becchetti R, Matteo C, Meroni M, Nastasi C, Cappelleri A, Frapolli R, Nardo G, Scanziani E, Ponzetta A, Bani MR, Ghilardi C, Giavazzi R., Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells., Oncoimmunology. 2023 Aug 1;12(1):2239035. doi: 10.1080/2162402X.2023.2239035. eCollection 2023.\n\nSen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., . . . Byers, L. A. (2017)., CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib., Cancer Research, 77(14), 3870-3884. doi:10.1158/0008-5472.CAN-16-3409 [doi]\n\nLi, J., Qu, X., Tian, J., Zhang, J. T., & Cheng, J. X. (2018)., Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation., PloS One, 13(2), e0193318. doi:10.1371/journal.pone.0193318 [doi]\n\nSobot, D., Mura, S., Rouquette, M., Vukosavljevic, B., Cayre, F., Buchy, E., . . . Couvreur, P. (2017)., Circulating lipoproteins: A trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells., Molecular Therapy : The Journal of the American Society of Gene Therapy, 25(7), 1596-1605. doi:S1525-0016(17)30234-4 [pii]\n\nYu, W., Chen, Y., Dubrulle, J., Stossi, F., Putluri, V., Sreekumar, A., . . . Sandulache, V. C. (2018)., Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism, Scientific Reports, 8(1), 4306-018-22640-y. doi:10.1038/s41598-018-22640-y [doi]\n\nTorna­n J, Mateu-Sanz M, Rey V, Murillo D, Huergo C, Gallego B, RodrÃ­guez A, RodrÃ­guez R, Canal C., Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma., Redox Biol. 2023 Jun;62:102685. doi: 10.1016/j.redox.2023.102685. Epub 2023 Mar 20.\n\nParsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA., Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer, Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Online ahead of print.\n\nParsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA., Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer, Mol Cancer Ther. 2021 Feb;20(2):263-273. doi: 10.1158/1535-7163.MCT-20-0365. Epub 2020 Dec 2.\n\nBelli, Valentina; Matrone, Nunzia; Napolitano, Stefania; Migliardi, Giorgia; Cottino, Francesca; Bertotti, Andrea; Trusolino, Livio; Martinelli, Erika; Morgillo, Floriana; Ciardiello, Davide; De Falco, Vincenzo; Giunta, Emilio Francesco; Bracale, Umberto; Ciardiello, Fortunato; Troiani, Teresa;, Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models., Journal of experimental & clinical cancer research : CR Vol.38, 2019\n\nFrost, S. H., Frayo, S. L., Miller, B. W., Orozco, J. J., Booth, G. C., Hylarides, M. D., . . . Press, O. W. (2015), Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models., PloS One, 10(3), e0120561. doi:10.1371/journal.pone.0120561 [doi]\n\nVugts, D. J., Klaver, C., Sewing, C., Poot, A. J., Adamzek, K., Huegli, S., . . . van Dongen, G. A. (2017)., Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)zr-immuno-PET., European Journal of Nuclear Medicine and Molecular Imaging, 44(2), 286-295. doi:10.1007/s00259-016-3499-x [doi]\n\nPattarawat P, Hong T, Wallace S, Hu Y, Donnell R, Wang TH, Tsai CL, Wang J, Wang HR., Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma, Br J Cancer. 2020 Jul;123(2):226-239. doi: 10.1038/s41416-020-0877-8. Epub 2020 May 11.\n\nKennedy AL, Rai R, Isingizwe ZR, Zhao YD, Lightfoot SA, Benbrook DM., Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib, Cancers (Basel). 2020 May 17;12(5):1269. doi: 10.3390/cancers12051269.\n\nShibata M, Ooki A, Inokawa Y, Sadhukhan P, Ugurlu MT, Izumchenko E, Munari E, Bogina G, Rudin CM, Gabrielson E, Singh A, Hoque MO., Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy, Mol Cancer Ther. 2020 Oct;19(10):2175-2185. doi: 10.1158/1535-7163.MCT-20-0024. Epub 2020 Aug 26.\n\nRestifo D, McDermott JR, Cvetkovic D, Dos Santos T, Ogier C, Surumbayeva A, Handorf EA, Schimke C, Ma C, Cai KQ, Olszanski AJ, Kathad U, Bhatia K, Sharma P, Kulkarni A, Astsaturov I., Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies., Mol Cancer Ther. 2023 Oct 2;22(10):1182-1190. doi: 10.1158/1535-7163.MCT-22-0818.\n\nPatel SS, Hoogenboezem EN, Yu F, DeJulius CR, Fletcher RB, Sorets AG, Cherry FK, Lo JH, Bezold MG, Francini N, d'Arcy R, Brasuell JE, Cook RS, Duvall CL., Core polymer optimization of ternary siRNA nanoparticles enhances in vivo safety, pharmacokinetics, and tumor gene silencing., Biomaterials. 2023 Jun;297:122098. doi: 10.1016/j.biomaterials.2023.122098. Epub 2023 Mar 28.\n\nLiu, Peng; Zhao, Liwei; Pol, Jonathan; Levesque, Sarah; Petrazzuolo, Adriana; Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen; Yamazaki, Takahiro; Iribarren, Kristina; Senovilla, Laura; Bezu, Lucillia; Vacchelli, Erika; Sica, Valentina; Melis, AndrĂŠa; Martin, Tiffany; Xia, Lin; Yang, Heng; Li, Qingqing; Chen, Jinfeng; Durand, SylvĂ¨re; Aprahamian, Fanny; Lefevre, Deborah; Broutin, Sophie; Paci, Angelo; Bongers, Amaury; Minard-Colin, Veronique; Tartour, Eric; Zitvogel, Laurence; Apetoh, Lionel; Ma, Yuting; Pittet, Mikael J; Kepp, Oliver; Kroemer, Guido;, Crizotinib-induced immunogenic cell death in non-small cell lung cancer, Nature communications Vol.10, 2019\n\nGrand-Guillaume J, Mansi R, Gaonkar RH, Zanger S, Fani M, Eugster PJ, Beck Popovic M, Grouzmann E, Abid K., CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors., J Transl Med. 2023 Sep 7;21(1):604. doi: 10.1186/s12967-023-04466-z.\n\nYamaguchi, M., Zhu, S., Zhang, S., Wu, D., Moore, T. M., Snyder, J. P., & Shoji, M. (2014)., Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: Involvement in osteoblastogenesis and osteoclastogenesis, Cell and Tissue Research, 357(1), 245-252. doi:10.1007/s00441-014-1846-4 [doi]\n\nDomanska, U. M., Boer, J. C., Timmer-Bosscha, H., van Vugt, M. A., Hoving, H. D., Kliphuis, N. M., . . . Walenkamp, A. M. (2014)., CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model, Clinical & Experimental Metastasis, 31(7), 829-839. doi:10.1007/s10585-014-9673-2 [doi]\n\nSharvit L, Bar-Shalom R, Azzam N, Yechiel Y, Wasser S, Fares F., Cyathus striatus Extract Induces Apoptosis in Human Pancreatic Cancer Cells and Inhibits Xenograft Tumor Growth In Vivo, Cancers (Basel). 2021 Apr 22;13(9):2017. doi: 10.3390/cancers13092017.\n\nGarcia, M., Velez, R., Romagosa, C., Majem, B., Pedrola, N., Olivan, M., . . . Doll, A. (2014)., Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice, BJU International, 113(5b), E164-77. doi:10.1111/bju.12503 [doi]\n\nKapoor S, Gustafson T, Zhang M, Chen YS, Li J, Nguyen N, Perez JET, Dashwood WM, Rajendran P, Dashwood RH., Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells, Cancers (Basel). 2021 Mar 22;13(6):1438. doi: 10.3390/cancers13061438.\n\nMcCarthy GA, Di Niro R, Finan JM, Jain A, Guo Y, Wyatt CR, Guimaraes AR, Waugh TA, Keith D, Morgan TK, Sears RC, Brody JR., Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity., NAR Cancer. 2023 Apr 19;5(2):zcad016. doi: 10.1093/narcan/zcad016. eCollection 2023 Jun.\n\nBayanbold K, Singhania M, Fath MA, Searby CC, Stolwijk JM, Henrich JB, Pulliam CF, Schoenfeld JD, Mapuskar KA, Sho S, Caster JM, Allen BG, Buettner GR, Spies M, Goswami PC, Petronek MS, Spitz DR., Depletion of Labile Iron Induces Replication Stress and Enhances Responses to Chemoradiation in Non-Small-Cell Lung Cancer., Antioxidants (Basel). 2023 Nov 15;12(11). pii: 2005. doi: 10.3390/antiox12112005.\n\nKinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, Hutchinson I, Vijayakrishnan B, McFarlane M, Ball K, Davies M, Lewis A, Huang Y, Rosenbaum AI, Yuan J, Chesebrough J, Anderton J, Monks N, Novick S, Wang J, Dimasi N, Christie RJ, et al., Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305., Clin Cancer Res. 2023 Mar 14;29(6):1086-1101. doi: 10.1158/1078-0432.CCR-22-2630.\n\nPerez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., . . . Jolly, D. J. (2012)., Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression, Molecular Therapy : The Journal of the American Society of Gene Therapy, 20(9), 1689-1698. doi:10.1038/mt.2012.83 [doi]\n\nNordmaj MA, Roberts ME, Sachse ES, Dagil R, Andersen AP, Skeltved N, Grunddal KV, Erdoğan SM, Choudhary S, Gustsavsson T, Ørum-Madsen MS, Moskalev I, Tian W, Yang Z, Clausen TM, Theander TG, Daugaard M, Nielsen MA, Salanti A., Development of a bispecific immune engager using a recombinant malaria protein, Cell Death Dis. 2021 Apr 6;12(4):353. doi: 10.1038/s41419-021-03611-0.\n\nMetwally K, Bastiancich C, Correard F, Novell A, Fernandez S, Guillet B, Larrat B, Mensah S, Estčve MA, Da Silva A., Development of a multi-functional preclinical device for the treatment of glioblastoma, Biomed Opt Express. 2021 Mar 23;12(4):2264-2279. doi: 10.1364/BOE.419412. eCollection 2021 Apr 1.\n\nD'Hollander, A., Mathieu, E., Jans, H., Vande Velde, G., Stakenborg, T., Van Dorpe, P., . . . Lagae, L. (2016), Development of nanostars as a biocompatible tumor contrast agent: Toward in vivo SERS imaging., International Journal of Nanomedicine, 11, 3703-3714. doi:10.2147/IJN.S91340 [doi]\n\nNavarro-Villaran, E., Tinoco, J., Jimenez, G., Pereira, S., Wang, J., Aliseda, S., . . . Muntane, J. (2016)., Differential antitumoral properties and renal-associated tissue damage induced by tacrolimus and mammalian target of rapamycin inhibitors in hepatocarcinoma: In vitro and in vivo studies, PloS One, 11(8), e0160979. doi:10.1371/journal.pone.0160979 [doi]\n\nZaher A, Mapuskar KA, Sarkaria JN, Spitz DR, Petronek MS, Allen BG., Differential H(2)O(2) Metabolism among Glioblastoma Subtypes Confers Variable Responses to Pharmacological Ascorbate Therapy Combined with Chemoradiation., Int J Mol Sci. 2023 Dec 5;24(24). pii: 17158. doi: 10.3390/ijms242417158.\n\nOksala, R., Moilanen, A., Riikonen, R., Rummakko, P., Karjalainen, A., Passiniemi, M., . . . Mustonen, M. V. (2018), Discovery and development of ODM-204: A novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1, The Journal of Steroid Biochemistry and Molecular Biology, doi:S0960-0760(18)30078-5 [pii]\n\nToader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, Chin CN, Dirksen A, Du B, Duvall JR, Higgins S, Kozytska MV, Bellovoda K, Faircloth C, Lee D, Li F, Qin L, Routhier C, Shaw P, Stevenson CA, Wang J, Wongthida P, et al., Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer., Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786.\n\nHiriyan, J., Shivarudraiah, P., Gavara, G., Annamalai, P., Natesan, S., Sambasivam, G., & Sukumaran, S. K. (2015)., Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models. Anticancer, Anticancer Research, 35(1), 229-237. doi:35/1/229 [pii]\n\nDonabedian, P. L., Kossatz, S., Engelbach, J. A., Jannetti, S. A., Carney, B., Young, R. J., . . . Reiner, T. (2018)., Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models., EJNMMI Research, 8(1), 59-018-0399-z. doi:10.1186/s13550-018-0399-z [doi]\n\nRidwan SM, El-Tayyeb F, Hainfeld JF, Smilowitz HM., Distributions of intravenous injected iodine nanoparticles in orthotopic u87 human glioma xenografts over time and tumor therapy, Nanomedicine (Lond). 2020 Oct;15(24):2369-2383. doi: 10.2217/nnm-2020-0178. Epub 2020 Sep 25.\n\nTuomela, J., Sandholm, J., Kaakinen, M., Patel, A., Kauppila, J. H., Ilvesaro, J., . . . Selander, K. S. (2013)., DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells., Breast Cancer Research and Treatment, 142(3), 477-487. doi:10.1007/s10549-013-2762-0 [doi]\n\nLaakso H, Ylä-Herttuala E, Sierra A, Jambor I, Poutanen M, Liljenbäck H, Virtanen H, Merisaari H, Aronen H, Minn H, Roivainen A, Liimatainen T., Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion, NMR Biomed. 2021 Apr;34(4):e4483. doi: 10.1002/nbm.4483. Epub 2021 Feb 4.\n\nYoungblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S, Lukas RV, Ahmed A, Unruh D, Walshon J, McCortney K, Wang Y, Baran A, Sahm F, Aldape K, Chandler JP, David James C, Heimberger AB, et al., Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas., Neuro Oncol. 2023 Mar 14;25(3):508-519. doi: 10.1093/neuonc/noac206.\n\nZhang Y, Wang Y, Valdivia A, Huang H, Matei D., DOT1 L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling., Mol Cancer Res. 2023 Feb 1;21(2):140-154. doi: 10.1158/1541-7786.MCR-22-0418.\n\nSciegienka, S. J., Solst, S. R., Falls, K. C., Schoenfeld, J. D., Klinger, A. R., Ross, N. L., . . . Fath, M. A. (2017)., D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress., Free Radical Biology & Medicine, 108, 354-361. doi:S0891-5849(17)30192-2 [pii]\n\nTsoneva, D., Stritzker, J., Bedenk, K., Zhang, Q., Frentzen, A., Cappello, J., . . . Szalay, A. A. (2015)., Drug-encoded biomarkers for monitoring biological therapies, PloS One, 10(9), e0137573. doi:10.1371/journal.pone.0137573 [doi]\n\nOhana, J., Sandler, U., Kass, G., Stemmer, S. M., & Devary, Y. (2017)., dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of golgi function., Molecular and Clinical Oncology, 7(6), 991-999. doi:10.3892/mco.2017.1453 [doi]\n\nKostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, Alexandridis R, Yu M, Hong S, Salgia R, Bruce JY, Birge RB, Harari PM, Wheeler DL., Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer., Head Neck. 2023 May;45(5):1255-1271. doi: 10.1002/hed.27340. Epub 2023 Mar 20.\n\nLuo, H., England, C. G., Shi, S., Graves, S. A., Hernandez, R., Liu, B., . . . Cai, W. (2016)., Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(15), 3821-3830. doi:10.1158/1078-0432.CCR-15-2054 [doi]\n\nKleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA., Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity., NPJ Precis Oncol. 2023 Feb 4;7(1):15. doi: 10.1038/s41698-023-00355-2.\n\nTan, Q., Joshua, A. M., Saggar, J. K., Yu, M., Wang, M., Kanga, N., . . . Tannock, I. F. (2015), Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy., British Journal of Cancer, 112(5), 832-840. doi:10.1038/bjc.2015.17 [doi]\n\nIonkina, A. A., Tentler, J. J., Kim, J., Capasso, A., Pitts, T. M., Ryall, K. A., . . . Diamond, J. R. (2017)., Efficacy and molecular mechanisms of differentiated response to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer., Frontiers in Oncology, 7, 94. doi:10.3389/fonc.2017.00094 [doi]\n\nKong, Y., Barisone, G. A., Sidhu, R. S., O'Donnell, R. T., & Tuscano, J. M. (2015)., Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human burkitt lymphoma., Molecular Medicine (Cambridge, Mass.), 21(1), 824-832. doi:10.2119/molmed.2015.00032 [doi]\n\nAkla, Barbara; Broussas, Matthieu; Loukili, Noureddine; Robert, Alain; Beau-Larvor, Charlotte; Malissard, Martine; Boute, Nicolas; Champion, Thierry; Haeuw, Jean-Francois; Beck, Alain; Perez, Michel; Dreyfus, Cyrille; Pavlyuk, Mariya; Chetaille, Eric; Corvaia, Nathalie;, Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors., Molecular cancer therapeutics Vol.19, 2020\n\nKang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, Young I, Malin CM, Kang Y, Gibbons DL, Sica G, Fu H, Ramalingam SS, Jin L, Kang S., EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer, Cell Rep. 2022 Dec 13;41(11):111827. doi: 10.1016/j.celrep.2022.111827.\n\nZalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung KM, Babu A, Battiste J, Chung J, Hwang K, Jin J, Towner RA., ELTD1 as a multi-focal target for malignant gliomas: preclinical studies, Neurooncol Adv. 2021 Sep 17;3(1):vdab132. doi: 10.1093/noajnl/vdab132. eCollection 2021 Jan-Dec.\n\nChoi, A. H., O'Leary, M. P., Lu, J., Kim, S. I., Fong, Y., & Chen, N. G. (2018), Endogenous akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvirus in triple-negative breast cancer., Molecular Therapy Oncolytics, 9, 22-29. doi:10.1016/j.omto.2018.04.001 [doi]\n\nNwagwu CD, Defensor E, Jiang MY, Rolle-McFarland DA, Carbonell AE, Carbonell WS., Endpoint in ovarian cancer xenograft model predicted by nighttime motion metrics, Lab Anim (NY). 2020 Aug;49(8):227-232. doi: 10.1038/s41684-020-0594-1. Epub 2020 Jul 20.\n\nSancho-Albero M, Facchetti G, Panini N, Meroni M, Bello E, Rimoldi I, Zucchetti M, Frapolli R, De Cola L., Enhancing Pt(IV) Complexes' Anticancer Activity upon Encapsulation in Stimuli-Responsive Nanocages., Adv Healthc Mater. 2023 Jul;12(17):e2202932. doi: 10.1002/adhm.202202932. Epub 2023 Mar 28.\n\nSiddique HR, Liao DJ, Mishra SK, Schuster T, Wang L, Matter B, Campbell PM, Villalta P, Nanda S, Deng Y, Saleem M., Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model, Int J Cancer. 2012 Oct 1;131(7):1720-31. doi: 10.1002/ijc.27409. Epub 2012 Feb 18.\n\nToden, S., Tran, H. M., Tovar-Camargo, O. A., Okugawa, Y., & Goel, A. (2016), Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer., Oncotarget, 7(13), 16158-16171. doi:10.18632/oncotarget.7567 [doi]\n\nWang, X., Tan, Y., Cao, X., Kim, J. A., Chen, T., Hu, Y., . . . Wang, X. (2018)., Epigenetic activation of HORMAD1 in basal-like breast cancer: Role in rucaparib sensitivity., Oncotarget, 9(53), 30115-30127. doi:10.18632/oncotarget.25728 [doi]\n\nEvans JS, Beaumont J, Braga M, Masrour N, Mauri F, Beckley A, Butt S, Karali CS, Cawthorne C, Archibald S, Aboagye EO, Sharma R., Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy, Eur J Cancer. 2022 Nov;176:110-120. doi: 10.1016/j.ejca.2022.09.009. Epub 2022 Oct 5.\n\nJauhiainen S, Ilmonen H, Vuola P, Rasinkangas H, Pulkkinen HH, KerÃ¤nen S, Kiema M, Liikkanen JJ, Laham-Karam N, Laidinen S, Beter M, Aavik E, Lappalainen K, Lohi J, Aronniemi J, Ã–rd T, Kaikkonen MU, Salminen P, Tukiainen E, YlÃ¤-Herttuala S, Laakkonen JP., ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component., Elife. 2023 May 18;12. pii: e82543. doi: 10.7554/eLife.82543.\n\nLi, D., & Marchenko, N. D. (2017), ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells, Oncotarget, 8(4), 5823-5833. doi:10.18632/oncotarget.12878 [doi]\n\nSchmitt, D. C., Madeira da Silva, L., Zhang, W., Liu, Z., Arora, R., Lim, S., . . . Tan, M. (2015)., ErbB2-intronic microRNA-4728: A novel tumor suppressor and antagonist of oncogenic MAPK signaling., Cell Death & Disease, 6, e1742. doi:10.1038/cddis.2015.116 [doi]\n\nBhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB., ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine, Mol Cancer Ther. 2020 Feb;19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183. Epub 2019 Nov 19.\n\nMaaland, Astri Fjelde; Heyerdahl, Helen; OShea, Adam; Eiriksdottir, Bergthora; Pascal, VĂŠronique; Andersen, Jan Terje; Kolstad, Arne; Dahle, Jostein;, European journal of nuclear medicine and molecular imaging Vol.46, 2019, European journal of nuclear medicine and molecular imaging Vol.46, 2019\n\nTuominen S, Keller T, Petruk N, LĂłpez-PicĂłn F, Eichin D, LĂśyttyniemi E, Verhassel A, Rajander J, Sandholm J, Tuomela J, GrĂśnroos TJ., Evaluation of [(18)F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy, Eur J Nucl Med Mol Imaging. 2020 Dec 19. doi: 10.1007/s00259-020-05115-z. Online ahead of print.\n\nTuominen S, Keller T, Petruk N, López-Picón F, Eichin D, Löyttyniemi E, Verhassel A, Rajander J, Sandholm J, Tuomela J, Grönroos TJ., Evaluation of [(18)F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy, Eur J Nucl Med Mol Imaging. 2021 May;48(5):1312-1326. doi: 10.1007/s00259-020-05115-z. Epub 2020 Dec 19.\n\nda Costa Rosa M, Yamashita AS, Riggins GJ., Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas, Neuro Oncol. 2022 May 4;24(5):711-723. doi: 10.1093/neuonc/noab263.\n\nRossi SM, Ryan BK, Kelly HM., Evaluation of the activity of a chemo-ablative, thermoresponsive hydrogel in a murine xenograft model of lung cancer, Br J Cancer. 2020 Aug;123(3):369-377. doi: 10.1038/s41416-020-0904-9. Epub 2020 May 27.\n\nScott, A. J., Song, E. K., Bagby, S., Purkey, A., McCarter, M., Gajdos, C., . . . Messersmith, W. A. (2017)., Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model., PloS One, 12(11), e0187173. doi:10.1371/journal.pone.0187173 [doi]\n\nScutigliani EM, Liang Y, IJff M, Rodermond H, Mei X, Korver MP, Orie VS, Hoebe RA, Picavet DI, Oei A, Kanaar R, Krawczyk PM., Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments, Cancers (Basel). 2022 Oct 26;14(21):5250. doi: 10.3390/cancers14215250.\n\nSiddiqui, I. A., Bharali, D. J., Nihal, M., Adhami, V. M., Khan, N., Chamcheu, J. C., . . . Mukhtar, H. (2014)., Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo., Nanomedicine : Nanotechnology, Biology, and Medicine, 10(8), 1619-1626. doi:10.1016/j.nano.2014.05.007 [doi]\n\nGonzalez-Sanchez L, Cobos-Fernandez MA, Lopez-Nieva P, Villa-Morales M, Stamatakis K, Cuezva JM, Marin-Rubio JL, Vazquez-Dominguez I, Gonzalez-Vasconcellos I, Salido E, Llamas P, Lopez-Lorenzo JL, Santos J, Fernandez-Piqueras J., Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells, Carcinogenesis. 2020 Aug 12;41(8):1113-1122. doi: 10.1093/carcin/bgz185.\n\nSperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L, Wang L, Yang R, Ren Y, Engle JW, Huang P, Kyriakopoulos CE, Slovin SF, Soule HR, Zhao SG, Kohli M, Tagawa ST, Cai W, et al., Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer., Clin Cancer Res. 2023 Jun 13;29(12):2324-2335. doi: 10.1158/1078-0432.CCR-22-1305.\n\nBownes LV, Williams AP, Marayati R, Stafman LL, Markert H, Quinn CH, Wadhwani N, Aye JM, Stewart JE, Yoon KJ, Mroczek-Musulman E, Beierle EA., EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth, PLoS One. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244. eCollection 2021.\n\nBownes LV, Williams AP, Marayati R, Stafman LL, Markert H, Quinn CH, Wadhwani N, Aye JM, Stewart JE, Yoon KJ, Mroczek-Musulman E, Beierle EA., EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth, PLoS One. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244. eCollection 2021.\n\nShen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C., FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells, Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23.\n\nShen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C., FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells, Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23.\n\nHicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE., Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2., Mol Cancer Res. 2023 Sep 1;21(9):867-880. doi: 10.1158/1541-7786.MCR-22-1031.\n\nCapasso, Anna; Bagby, Stacey M; Dailey, Kyrie L; Currimjee, Naomi; Yacob, Betelehem W; Ionkina, Anastasia; Frank, Julie G; Kim, Deog Joong; George, Christina; Lee, Young B; Benaim, Ely; Gittleman, Brian; Hartman, Sarah J; Tan, Aik Choon; Kim, Jihye; Pitts, Todd M; Eckhardt, S Gail; Tentler, John J; Diamond, Jennifer R;, First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ??-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer, Molecular cancer therapeutics Vol.18, 2019\n\nXu, L., Yeudall, W. A., & Yang, H. (2017)., Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery., Acta Biomaterialia, 57, 251-261. doi:S1742-7061(17)30262-3 [pii]\n\nFaugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, Marty V, Alexandrova K, Andree KC, Stoecklein NH, Tramalloni D, Cairo S, NgoCamus M, Nicotra C, Terstappen LWMM, Manaresi N, Lapierre V, Fizazi K, Scoazec JY, Loriot Y, Judde JG, Farace F., Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model, Nat Commun. 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2.\n\nSasaki, K., Kurahara, H., Young, E. D., Natsugoe, S., Ijichi, A., Iwakuma, T., & Welch, D. R. (2017)., Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer., Clinical & Experimental Metastasis, 34(3-4), 229-239. doi:10.1007/s10585-017-9840-3 [doi]\n\nLampa, M., Arlt, H., He, T., Ospina, B., Reeves, J., Zhang, B., . . . Srinivasan, L. (2017)., Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition, PloS One, 12(9), e0185092. doi:10.1371/journal.pone.0185092 [doi]\n\nSharp PS, Stylianou M, Arellano LM, Neves JC, Gravagnuolo AM, Dodd A, Barr K, Lozano N, Kisby T, Kostarelos K., Graphene Oxide Nanoscale Platform Enhances the Anti-Cancer Properties of Bortezomib in Glioblastoma Models, Adv Healthc Mater. 2023 Jan;12(3):e2201968. doi: 10.1002/adhm.202201968. Epub 2022 Nov 11.\n\nSorin, V., Ohana, P., Gallula, J., Birman, T., Matouk, I., Hubert, A., . . . Czerniak, A. (2012)., H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer, ISRN Oncology, 2012, 351750. doi:10.5402/2012/351750 [doi]\n\nZhou, Y., Li, G., Zhu, L., Li, C., Cornelius, L. A., & Wang, L. V. (2015)., Handheld photoacoustic probe to detect both melanoma depth and volume at high speed in vivo., Journal of Biophotonics, 8(11-12), 961-967. doi:10.1002/jbio.201400143 [doi]\n\nCui J, Xu F, Bai W, Zhao T, Hong J, Zuo W., HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism., J Transl Med. 2023 Feb 15;21(1):125. doi: 10.1186/s12967-023-03973-3.\n\nChomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ., Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET, Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):694-707. doi: 10.1007/s00259-020-05002-7. Epub 2020 Sep 5.\n\nArzumanyan, A., Sambandam, V., Clayton, M. M., Choi, S. S., Xie, G., Diehl, A. M., . . . Feitelson, M. A. (2012)., Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein., Cancer Research, 72(22), 5912-5920. doi:10.1158/0008-5472.CAN-12-2329 [doi]\n\nElwaie TA, Abbas SE, Aly EI, George RF, Ali H, Kraiouchkine N, Abdelwahed KS, Fandy TE, El Sayed KA, Abd Elmageed ZY, Ali HI., HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability, J Med Chem. 2020 Dec 24;63(24):15906-15945. doi: 10.1021/acs.jmedchem.0c01647. Epub 2020 Dec 14.\n\nPhillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE., Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors, Cancer Res. 2021 Jun 15;81(12):3402-3414. doi: 10.1158/0008-5472.CAN-20-2178. Epub 2021 Mar 9.\n\nSánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V., High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2021 Sep 30. doi: 10.1158/1078-0432.CCR-21-1810. Online ahead of print.\n\nSánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V., High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2022 Jan 1;28(1):137-149. doi: 10.1158/1078-0432.CCR-21-1810. Epub 2021 Sep 30.\n\nHuhtaniemi R, Sipilä P, Junnila A, Oksala R, Knuuttila M, Mehmood A, Aho E, Laajala TD, Aittokallio T, Laiho A, Elo L, Ohlsson C, Thulin MH, Kallio P, Mäkelä S, Mustonen MVJ, Poutanen M., High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice, iScience. 2022 Apr 25;25(5):104287. doi: 10.1016/j.isci.2022.104287. eCollection 2022 May 20.\n\nKumar N, Rachagani S, Natarajan G, Crook A, Gopal T, Rajamanickam V, Kaushal JB, Nagabhishek SN, Powers R, Batra SK, Saraswathi V., Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant-Antioxidant Balance., Cancers (Basel). 2023 May 3;15(9). pii: 2593. doi: 10.3390/cancers15092593.\n\nEfimova, E. V., Ricco, N., Labay, E., Mauceri, H. J., Flor, A. C., Ramamurthy, A., . . . Kron, S. J. (2018)., HMG-CoA reductase inhibition delays DNA repair and promotes senescence after tumor irradiation., Molecular Cancer Therapeutics, 17(2), 407-418. doi:10.1158/1535-7163.MCT-17-0288 [doi]\n\nLelj-Garolla, B., Kumano, M., Beraldi, E., Nappi, L., Rocchi, P., Ionescu, D. N., . . . Gleave, M. E. (2015)., Hsp27 inhibition with OGX-427 sensitizes non-small cell lung cancer cells to erlotinib and chemotherapy., Molecular Cancer Therapeutics, 14(5), 1107-1116. doi:10.1158/1535-7163.MCT-14-0866 [doi]\n\nLu J, Chen L, Song Z, Das M, Chen J., Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations, Cancer Res. 2021 Jul 15;81(14):3905-3915. doi: 10.1158/0008-5472.CAN-21-0033. Epub 2021 Mar 9.\n\nLu, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018)., Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1., Molecular Cancer Research : MCR, 16(10), 1458-1469. doi:10.1158/1541-7786.MCR-17-0637 [doi]\n\nLu, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018)., Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1., Molecular Cancer Research : MCR, 16(10), 1458-1469. doi:10.1158/1541-7786.MCR-17-0637 [doi]\n\nSerra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ., Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance, Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568.\n\nFell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA., Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer, J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6.\n\nAbourbeh, G., Itamar, B., Salnikov, O., Beltsov, S., & Mishani, E. (2015)., Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET., EJNMMI Research, 5, 4-014-0080-0. eCollection 2015. doi:10.1186/s13550-014-0080-0 [doi]\n\nGargini R, Segura-Collar B, Garranzo-Asensio M, Hortigüela R, Iglesias-Hernández P, Lobato-Alonso D, Moreno-Raja M, Esteban-Martin S, Sepúlveda-Sánchez JM, Nevola L, Sánchez-Gómez P., IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas, Neurotherapeutics. 2022 Jan;19(1):408-420. doi: 10.1007/s13311-021-01176-6. Epub 2022 Jan 31.\n\nAttaluri, A., Seshadri, M., Mirpour, S., Wabler, M., Marinho, T., Furqan, M., . . . Liapi, E. (2016), Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. International Journal of Hyperthermia, The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 32(5), 543-557. doi:10.3109/02656736.2016.1159737 [doi]\n\nBrignole, C., Pastorino, F., Marimpietri, D., Pagnan, G., Pistorio, A., Allen, T. M., . . . Ponzoni, M. (2004)., Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs., Journal of the National Cancer Institute, 96(15), 1171-1180. doi:10.1093/jnci/djh221 [doi]\n\nAlvero AB, Fox A, Madina BR, Krady MM, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky TO, Rutherford T, Mor G., Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory., Cancer Immunol Res. 2023 Dec 11. doi: 10.1158/2326-6066.CIR-23-0127. [Epub ahead of print]\n\nSun, H., England, C. G., Hernandez, R., Graves, S. A., Majewski, R. L., Kamkaew, A., . . . Cai, W. (2016)., ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer, European Journal of Nuclear Medicine and Molecular Imaging, 43(12), 2169-2179. doi:10.1007/s00259-016-3442-1 [doi]\n\nHernandez, R., England, C. G., Yang, Y., Valdovinos, H. F., Liu, B., Wong, H. C., . . . Cai, W. (2017)., ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)zr-df-ALT-836, Journal of Controlled Release : Official Journal of the Controlled Release Society, 264, 160-168. doi:S0168-3659(17)30796-4 [pii]\n\nLi M, Wei W, Barnhart TE, Jiang D, Cao T, Fan K, Engle JW, Liu J, Chen W, Cai W., ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma, Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2737-2748. doi: 10.1007/s00259-021-05216-3. Epub 2021 Feb 3.\n\nGuffanti F, Alvisi MF, Caiola E, Ricci F, De Maglie M, Soldati S, Ganzinelli M, Decio A, Giavazzi R, Rulli E, Damia G., Impact of ERCC1, XPF and DNA Polymerase ? Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts, Cancers (Basel). 2020 Aug 24;12(9):2398. doi: 10.3390/cancers12092398.\n\nHeinrich, A. K., Lucas, H., Schindler, L., Chytil, P., Etrych, T., Mader, K., & Mueller, T. (2016), Improved tumor-specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance, Molecular Cancer Therapeutics, 15(5), 998-1007. doi:10.1158/1535-7163.MCT-15-0824 [doi]\n\nHughes, P. E., Rex, K., Caenepeel, S., Yang, Y., Zhang, Y., Broome, M. A., . . . Coxon, A. (2016)., In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models., Molecular Cancer Therapeutics, 15(7), 1568-1579. doi:10.1158/1535-7163.MCT-15-0871 [doi]\n\nBaldini E, Presutti D, Favoriti P, Santini S, Papoff G, Tuccilli C, Carletti R, Di Gioia C, Lori E, Ferent IC, Gagliardi F, Catania A, Pironi D, Tripodi D, D'Andrea V, Sorrenti S, Ruberti G, Ulisse S., In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines, Int J Mol Sci. 2022 Mar 28;23(7):3724. doi: 10.3390/ijms23073724.\n\nXia, C. F., Chen, G., Gangadharmath, U., Gomez, L. F., Liang, Q., Mu, F., . . . Kolb, H. C. (2013), In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer [(18)F]-CP18 for PET imaging of apoptosis in tumors., Molecular Imaging and Biology : MIB : The Official Publication of the Academy of Molecular Imaging, 15(6), 748-757. doi:10.1007/s11307-013-0646-7 [doi]\n\nTakahashi-Ruiz L, Morris JD, Crews P, Johnson TA, Risinger AL., In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and Persistent Antitumor Efficacy When Targeted to the Tumor Site, Molecules. 2022 Jul 1;27(13):4244. doi: 10.3390/molecules27134244.\n\nHe, Y., Wang, L., Shi, J., Yao, J., Li, L., Zhang, R., . . . Wang, L. V. (2016), In vivo label-free photoacoustic flow cytography and on-the-spot laser killing of single circulating melanoma cells, Scientific Reports, 6, 39616. doi:10.1038/srep39616 [doi]\n\nIrrera P, Consolino L, Roberto M, Capozza M, Dhakan C, Carella A, Corrado A, Villano D, Anemone A, Navarro-Tableros V, Bracesco M, Dastrù W, Aime S, Longo DL., In Vivo MRI-CEST Tumor pH Imaging Detects Resistance to Proton Pump Inhibitors in Human Prostate Cancer Murine Models, Cancers (Basel). 2022 Oct 7;14(19):4916. doi: 10.3390/cancers14194916.\n\nRybczynska, A. A., de Bruyn, M., Ramakrishnan, N. K., de Jong, J. R., Elsinga, P. H., Helfrich, W., . . . van Waarde, A. (2013)., In vivo responses of human A375M melanoma to a sigma ligand: 18F-FDG PET imaging., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 54(9), 1613-1620. doi:10.2967/jnumed.113.122655 [doi]\n\nColmegna, B., Uboldi, S., Frapolli, R., Licandro, S. A., Panini, N., Galmarini, C. M., . . . D'Incalci, M. (2015), Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin., British Journal of Cancer, 113(12), 1687-1693. doi:10.1038/bjc.2015.407 [doi]\n\nGunsalus, K. T., Wagoner, M. P., Meyer, K., Potter, W. B., Schoenike, B., Kim, S., . . . Roopra, A. (2012)., Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors, Cancer Research, 72(13), 3207-3216. doi:10.1158/0008-5472.CAN-11-1639 [doi]\n\nWang, X., Solban, N., Khanna, P., Callea, M., Song, J., Alsop, D. C., . . . Bhatt, R. S. (2016)., Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma., Oncotarget, 7(27), 41857-41869. doi:10.18632/oncotarget.9621 [doi]\n\nZhou Q, Howard ME, Tu X, Zhu Q, Denbeigh JM, Remmes NB, Herman MG, Beltran CJ, Yuan J, Greipp PT, Boughey JC, Wang L, Johnson N, Goetz MP, Sarkaria JN, Lou Z, Mutter RW., Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining, Cancer Res. 2021 Jun 15;81(12):3333-3346. doi: 10.1158/0008-5472.CAN-20-2960. Epub 2021 Feb 17.\n\nCook Sangar, M. L., Genovesi, L. A., Nakamoto, M. W., Davis, M. J., Knobluagh, S. E., Ji, P., . . . Olson, J. M. (2017)., Inhibition of CDK4/6 by palbociclib significantly extends survival in medulloblastoma patient-derived xenograft mouse models., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(19), 5802-5813. doi:10.1158/1078-0432.CCR-16-2943 [doi]\n\nLuna AJ, Young JM, Sterk RT, Bondu V, Schultz FA, Kusewitt DF, Kang H, Ozbun MA., Inhibition of Cellular MEK/ERK Signaling Suppresses Murine Papillomavirus Type 1 Replicative Activities and Promotes Tumor Regression., bioRxiv. 2023 Apr 24. pii: 2023.03.14.532042. doi: 10.1101/2023.03.14.532042. Update in: Antiviral Res. 2023 Aug;216:105667.\n\nZhang, Y., Wang, Q., Chen, L., & Yang, H. S. (2015), Inhibition of p70S6K1 activation by Pdcd4 overcomes the resistance to an IGF-1R/IR inhibitor in colon carcinoma cells., Molecular Cancer Therapeutics, 14(3), 799-809. doi:10.1158/1535-7163.MCT-14-0648 [doi]\n\nShao, C., Ahmad, N., Hodges, K., Kuang, S., Ratliff, T., & Liu, X. (2015)., Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer., The Journal of Biological Chemistry, 290(4), 2024-2033. doi:10.1074/jbc.M114.596817 [doi]\n\nGómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart M, Sotiriou C, González-Suárez E., Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells, Nat Commun. 2020 Dec 10;11(1):6335. doi: 10.1038/s41467-020-20138-8.\n\nHumeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, Bezu L, Lévesque S, Paillet J, Pol J, Leduc M, Zitvogel L, de Thé H, Kepp O, Kroemer G., Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress, EMBO Mol Med. 2020 May 8;12(5):e11622. doi: 10.15252/emmm.201911622. Epub 2020 Apr 23.\n\nCao W, Shen R, Richard S, Liu Y, Jalalirad M, Cleary MP, D'Assoro AB, Gradilone SA, Yang DQ., Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt, Oncol Rep. 2022 Feb;47(2):41. doi: 10.3892/or.2021.8252. Epub 2021 Dec 27.\n\nZhou K, Cheong JE, Krishnaji ST, Ghalali A, Fu H, Sui L, Alix-Panabières C, Cayrefourcq L, Bielenberg D, Sun L, Zetter B., Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation, Mol Cancer Ther. 2023 Jan 3;22(1):25-36. doi: 10.1158/1535-7163.MCT-21-0801.\n\nPuente, P., Fettig, N., Luderer, M. J., Jin, A., Shah, S., Muz, B., . . . Azab, A. K. (2018)., Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors., Journal of Pharmaceutical Sciences, 107(3), 922-933. doi:S0022-3549(17)30829-8 [pii]\n\nWu, Jiao; Minikes, Alexander M; Gao, Minghui; Bian, Huijie; Li, Yong; Stockwell, Brent R; Chen, Zhi-Nan; Jiang, Xuejun;, Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling, Nature Vol.572, 2019\n\nHwang SY, Park S, Jo H, Hee Seo S, Jeon KH, Kim S, Jung AR, Song C, Ahn M, Yeon Kwak S, Lee HJ, Uesugi M, Na Y, Kwon Y., Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers, J Adv Res. 2022 Aug 10:S2090-1232(22)00171-0. doi: 10.1016/j.jare.2022.08.003. Online ahead of print.\n\nHwang SY, Park S, Jo H, Hee Seo S, Jeon KH, Kim S, Jung AR, Song C, Ahn M, Yeon Kwak S, Lee HJ, Uesugi M, Na Y, Kwon Y., Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers., J Adv Res. 2023 May;47:173-187. doi: 10.1016/j.jare.2022.08.003. Epub 2022 Aug 10.\n\nEyme KM, Carvalho L, Badr CE., Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models, STAR Protoc. 2021 Jan 21;2(1):100290. doi: 10.1016/j.xpro.2020.100290. eCollection 2021 Mar 19.\n\nWang, W., Cho, H. Y., Rosenstein-Sisson, R., Marin Ramos, N. I., Price, R., Hurth, K., . . . Chen, T. C. (2018), Intratumoral delivery of bortezomib: Impact on survival in an intracranial glioma tumor model, Journal of Neurosurgery, 128(3), 695-700. doi:10.3171/2016.11.JNS161212 [doi]\n\nRelation, T., Yi, T., Guess, A. J., La Perle, K., Otsuru, S., Hasgur, S., . . . Horwitz, E. M. (2018)., Intratumoral delivery of interferongamma-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo., Stem Cells (Dayton, Ohio), 36(6), 915-924. doi:10.1002/stem.2801 [doi]\n\nEluu SC, Obayemi JD, Salifu AA, Yiporo D, Oko AO, Aina T, Oparah JC, Ezeala CC, Etinosa PO, Ugwu CM, Esimone CO, Soboyejo WO., In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer., Sci Rep. 2024 Jan 2;14(1):31. doi: 10.1038/s41598-023-50656-6.\n\nTurchan, W. T., Shapiro, R. H., Sevigny, G. V., Chin-Sinex, H., Pruden, B., & Mendonca, M. S. (2016)., Irradiated human endothelial progenitor cells induce bystander killing in human non-small cell lung and pancreatic cancer cells, International Journal of Radiation Biology, 92(8), 427-433. doi:10.1080/09553002.2016.1186299 [doi]\n\nWu Q, Tian AL, Durand S, Aprahamian F, Nirmalathasan N, Xie W, Liu P, Zhao L, Zhang S, Pan H, Carmona-Gutierrez D, Madeo F, Tu Y, Kepp O, Kroemer G., Isobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy, Cell Death Dis. 2020 Nov 26;11(11):1015. doi: 10.1038/s41419-020-03226-x.\n\nBouguenina H, Nicolaou S, Le Bihan YV, Bowling EA, Calderon C, Caldwell JJ, Harrington B, Hayes A, McAndrew PC, Mitsopoulos C, Sialana FJ, Scarpino A, Stubbs M, Thapaliya A, Tyagi S, Wang HZ, Wood F, Burke R, Raynaud F, Choudhary J, van Montfort RLM, Sadok A, et al., iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells., iScience. 2023 Jun 7;26(7):107059. doi: 10.1016/j.isci.2023.107059. eCollection 2023 Jul 21.\n\nImig JD, Hye Khan MA, Burkhan A, Chen G, Adebesin AM, Falck JR., Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity, Int J Mol Sci. 2021 Mar 10;22(6):2793. doi: 10.3390/ijms22062793.\n\nGelsomino L, Naimo GD, Malivindi R, Augimeri G, Panza S, Giordano C, Barone I, Bonofiglio D, Mauro L, Catalano S, AndĂ˛ S., Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression, Cancers (Basel). 2020 Jul 27;12(8):2078. doi: 10.3390/cancers12082078.\n\nDwivedi SKD, Shameer K, Dey A, Mustafi SB, Xiong X, Bhattacharya U, Neizer-Ashun F, Rao G, Wang Y, Ivan C, Yang D, Dudley JT, Xu C, Wren JD, Mukherjee P, Bhattacharya R., KRCC1: A potential therapeutic target in ovarian cancer, FASEB J. 2020 Feb;34(2):2287-2300. doi: 10.1096/fj.201902259R. Epub 2019 Dec 23.\n\nEskra, Jillian N; Schlicht, Michael J; Bosland, Maarten C;, Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer., The Prostate Vol.79, 2019\n\nPascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM., Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma, Biochem Pharmacol. 2023 Jan 2;208:115408. doi: 10.1016/j.bcp.2022.115408. Online ahead of print.\n\nPascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, BurgueÃ±o V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM., Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma., Biochem Pharmacol. 2023 Feb;208:115408. doi: 10.1016/j.bcp.2022.115408. Epub 2023 Jan 2.\n\nHaedicke, K., Graefe, S., Teichgraeber, U., & Hilger, I. (2016)., Lowering photosensitizer doses and increasing fluences induce apoptosis in tumor bearing mice, Biomedical Optics Express, 7(7), 2641-2649. doi:10.1364/BOE.7.002641 [doi]\n\nSantamaria Nunez, G., Robles, C. M., Giraudon, C., Martinez-Leal, J. F., Compe, E., Coin, F., . . . Egly, J. M. (2016)., Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells., Molecular Cancer Therapeutics, 15(10), 2399-2412. doi:1535-7163.MCT-16-0172 [pii]\n\nJohnson, J. L., Dia, V. P., Wallig, M., & Gonzalez de Mejia, E. (2015), Luteolin and gemcitabine protect against pancreatic cancer in an orthotopic mouse model., Pancreas, 44(1), 144-151. doi:10.1097/MPA.0000000000000215 [doi]\n\nSchregel K, Nowicki MO, Palotai M, Nazari N, Zane R, Sinkus R, Lawler SE, Patz S., Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model, Cancer Imaging. 2020 May 12;20(1):35. doi: 10.1186/s40644-020-00314-1.\n\nRoger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A., Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy, Cells. 2020 Sep 16;9(9):2110. doi: 10.3390/cells9092110.\n\nLodestijn SC, Miedema DM, Lenos KJ, Nijman LE, Belt SC, El Makrini K, Lecca MC, Waasdorp C, van den Bosch T, Bijlsma MF, Vermeulen L., Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer, Cell Rep. 2021 Oct 19;37(3):109852. doi: 10.1016/j.celrep.2021.109852.\n\nBernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J., Mujagic, A., . . . Sheng, S. (2015), Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity, Cancer Research, 75(18), 3970-3979. doi:10.1158/0008-5472.CAN-15-0234 [doi]\n\nKalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM, Marjon K., MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage, Cancer Cell. 2021 Feb 8;39(2):209-224.e11. doi: 10.1016/j.ccell.2020.12.010. Epub 2021 Jan 14.\n\nCrotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM., Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival, J Neurooncol. 2021 Jun;153(2):225-237. doi: 10.1007/s11060-021-03767-x. Epub 2021 May 8.\n\nFranklin DA, Sharick JT, Ericsson-Gonzalez PI, Sanchez V, Dean PT, Opalenik SR, Cairo S, Judde JG, Lewis MT, Chang JC, Sanders ME, Cook RS, Skala MC, Bordeaux J, Orozco Bender J, Vaupel C, Geiss G, Hinerfeld D, Balko JM., MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC, JCI Insight. 2020 Aug 6;5(15):e134290. doi: 10.1172/jci.insight.134290.\n\nGarcía-García , Celina; Rivas, Martín A; Ibrahim, Yasir H; Calvo, María Teresa; Gris-Oliver, Albert; Rodríguez , Olga; Grueso, Judit; Antón, Pilar; Guzmán, Marta; Aura, Claudia; Nuciforo, Paolo; Jessen, Katti; Argilés, Guillem; Dienstmann, Rodrigo; Bertotti, Andrea; Trusolino, Livio; Matito, Judit; Vivancos, Ana; Chicote, Irene; Palmer, Héctor G; Tabernero, Josep; Scaltriti, Maurizio; Baselga, José; Serra, Violeta, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clinical cancer research : an official journal of the American Association for Cancer Research Vol.21, 2015\n\nRamesh S, Cifci A, Javeri S, Minne R, Longhurst CA, Nickel KP, Kimple RJ, Baschnagel AM., MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer., bioRxiv. 2023 Oct 27. pii: 2023.10.26.564232. doi: 10.1101/2023.10.26.564232. Update in: Int J Radiat Oncol Biol Phys. 2023 Nov 16;:.\n\nSharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, Choudhary A, Garcia-Valera R, Burkard ME, McGregor SM, Matkowskyj KA, Parikh AA, Meszoely IM, Kelley MC, Tsai S, Deming DA, Skala MC., Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment, Front Oncol. 2020 May 15;10:553. doi: 10.3389/fonc.2020.00553. eCollection 2020.\n\nMascaraque-Checa M, Gallego-Rentero M, Nicolás-Morala J, Portillo-Esnaola M, Cuezva JM, González S, Gilaberte Y, Juarranz Á., Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy, Mol Metab. 2022 Jun;60:101496. doi: 10.1016/j.molmet.2022.101496. Epub 2022 Apr 9.\n\nYan, S. B., Um, S. L., Peek, V. L., Stephens, J. R., Zeng, W., Konicek, B. W., . . . Walgren, R. A. (2018)., MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping., Investigational New Drugs, 36(4), 536-544. doi:10.1007/s10637-017-0545-x [doi]\n\nAl-Jamal WT, Kostarelos K., Mild hyperthermia accelerates doxorubicin clearance from tumour-extravasated temperature-sensitive liposomes, Nanotheranostics. 2022 Jan 1;6(3):230-242. doi: 10.7150/ntno.61280. eCollection 2022.\n\nPunturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S., Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer, Nat Commun. 2021 May 19;12(1):2940. doi: 10.1038/s41467-021-23271-0.\n\nGonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM., Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer, Cancer Discov. 2021 Jul;11(7):1672-1687. doi: 10.1158/2159-8290.CD-20-1683. Epub 2021 Feb 25.\n\nLv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, et al., Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors., Science. 2023 Sep 8;381(6662):eabn4180. doi: 10.1126/science.abn4180. Epub 2023 Sep 8.\n\nYan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G., Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.\n\nYan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G., Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.\n\nMorcillo, M. A., Garcia de Lucas, A., Oteo, M., Romero, E., Magro, N., Ibanez, M., . . . Martinez-Torrecuadrada, J. (2018)., MT1-MMP as a PET imaging biomarker for pancreas cancer management., Contrast Media & Molecular Imaging, 2018, 8382148. doi:10.1155/2018/8382148 [doi]\n\nKumar, A., Dhar, S., Campanelli, G., Butt, N. A., Schallheim, J. M., Gomez, C. R., & Levenson, A. S. (2018), MTA1 drives malignant progression and bone metastasis in prostate cancer., Molecular Oncology, 12(9), 1596-1607. doi:10.1002/1878-0261.12360 [doi]\n\nHaedicke, K., Kozlova, D., Grafe, S., Teichgraber, U., Epple, M., & Hilger, I. (2015)., Multifunctional calcium phosphate nanoparticles for combining near-infrared fluorescence imaging and photodynamic therapy, Acta Biomaterialia, 14, 197-207. doi:10.1016/j.actbio.2014.12.009 [doi]\n\nHuang H, Zhao G, Cardenas H, Valdivia AF, Wang Y, Matei D., N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase., Mol Cancer Ther. 2023 Mar 2;22(3):393-405. doi: 10.1158/1535-7163.MCT-22-0278.\n\nPeddi S, Roberts SK, MacKay JA., Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer, Biomacromolecules. 2020 Mar 9;21(3):1091-1102. doi: 10.1021/acs.biomac.9b01431. Epub 2020 Feb 6.\n\nZhu Y, Yue P, Dickinson CF, Yang JK, Datanagan K, Zhai N, Zhang Y, Miklossy G, Lopez-Tapia F, Tius MA, Turkson J., Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo, Cell Death Dis. 2022 Dec 6;13(12):1022. doi: 10.1038/s41419-022-05477-2.\n\nVeeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R., Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models, NPJ Breast Cancer. 2021 May 27;7(1):63. doi: 10.1038/s41523-021-00274-0.\n\nWang, P. Y., Swain, H. M., Kunkler, A. L., Chen, C. Y., Hutzen, B. J., Arnold, M. A., . . . Cripe, T. P. (2016)., Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility., Gene Therapy, 23(2), 135-143. doi:10.1038/gt.2015.105 [doi]\n\nZheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC., Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer, Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.\n\nLi X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D., Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models., Br J Cancer. 2023 Sep;129(5):884-894. doi: 10.1038/s41416-023-02359-y. Epub 2023 Jul 20.\n\nYu, X., Liu, F., Zeng, L., He, F., Zhang, R., Yan, S., . . . Chen, L. (2018)., Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells., Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 47(3), 957-971. doi:10.1159/000490140 [doi]\n\nBousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, CaĂąamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A., Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma, J Clin Invest. 2020 Feb 3;130(2):612-624. doi: 10.1172/JCI126896.\n\nChen, H., Jacobson, O., Niu, G., Weiss, I. D., Kiesewetter, D. O., Liu, Y., . . . Chen, X. (2017)., Novel \"add-on\" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents. Journal of Nuclear Medicin, Official Publication, Society of Nuclear Medicine, 58(4), 590-597. doi:10.2967/jnumed.116.182097 [doi]\n\nChoi, A. H., O'Leary, M. P., Chaurasiya, S., Lu, J., Kim, S. I., Fong, Y., & Chen, N. G. (2018)., Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer, Surgery, 163(2), 336-342. doi:S0039-6060(17)30670-0 [pii]\n\nKleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE., Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response, Cancer Lett. 2023 Jan 16:216062. doi: 10.1016/j.canlet.2023.216062. Online ahead of print.\n\nKleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE., Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response., Cancer Lett. 2023 Mar 1;556:216062. doi: 10.1016/j.canlet.2023.216062. Epub 2023 Jan 16.\n\nKanthala, S., Banappagari, S., Gokhale, A., Liu, Y. Y., Xin, G., Zhao, Y., & Jois, S. (2015)., Novel peptidomimetics for inhibition of HER2:HER3 heterodimerization in HER2-positive breast cancer., Chemical Biology & Drug Design, 85(6), 702-714. doi:10.1111/cbdd.12453 [doi]\n\nMarayati R, Williams AP, Bownes LV, Quinn CH, Stewart JE, Mroczek-Musulman E, Atigadda VR, Beierle EA., Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma, J Pediatr Surg. 2020 Jun;55(6):1072-1080. doi: 10.1016/j.jpedsurg.2020.02.027. Epub 2020 Feb 28.\n\nChen Y, Li X, Mamouni K, Yang Y, Danaher A, White J, Liu H, Kucuk O, Gera L, Wu D., Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer, Prostate. 2020 Sep;80(12):993-1005. doi: 10.1002/pros.24032. Epub 2020 Jun 19.\n\nGdowski A, Hayatshahi H, Fudala R, Joshi R, Liu J, Vishwanatha JK, Jeyarajah R, Guzik P, Ranjan AP., Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer, Pharmaceutics. 2022 Jan 5;14(1):128. doi: 10.3390/pharmaceutics14010128.\n\nHegde, Ganapati V; de la Cruz, Cecile; Giltnane, Jennifer M; Crocker, Lisa; Venkatanarayan, Avinashnarayan; Schaefer, Gabriele; Dunlap, Debra; Hoeck, Joerg D; Piskol, Robert; Gnad, Florian; Modrusan, Zora; de Sauvage, Frederic J; Siebel, Christian W; Jackson, Erica L;, NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma, eLife Vol.8, 2019\n\nSomwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA., NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors, Commun Biol. 2020 Dec 16;3(1):776. doi: 10.1038/s42003-020-01508-w.\n\nServetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, Arteaga CL., Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer, Clin Cancer Res. 2021 Aug 1;27(15):4379-4396. doi: 10.1158/1078-0432.CCR-20-3905. Epub 2021 May 19.\n\nYi J, Zhu J, Wu J, Thompson CB, Jiang X., Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis, Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31189-31197. doi: 10.1073/pnas.2017152117. Epub 2020 Nov 23.\n\nVasciaveo A, Arriaga JM, de Almeida FN, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, et al., OncoLoop: A Network-Based Precision Cancer Medicine Framework., Cancer Discov. 2023 Feb 6;13(2):386-409. doi: 10.1158/2159-8290.CD-22-0342.\n\nKottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, Huff AL, Zell B, Thompson JM, Wongthida P, Pulido J, Schuelke MR, Samson A, Selby P, Ilett E, McNiven M, Roberts LR, Borad MJ, Pandha H, Harrington K, Melcher A, Vile RG., Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy, Nat Commun. 2021 Mar 26;12(1):1930. doi: 10.1038/s41467-021-22115-1.\n\nLagerweij, T., Dusoswa, S. A., Negrean, A., Hendrikx, E. M. L., de Vries, H. E., Kole, J., . . . Wurdinger, T. (2017)., Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment., Angiogenesis, 20(4), 533-546. doi:10.1007/s10456-017-9565-6 [doi]\n\nWalsh, Alex J; Castellanos, Jason A; Nagathihalli, Nagaraj S; Merchant, Nipun B; Skala, Melissa C;, Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response., Pancreas Vol.45, 2016\n\nPearson, H. E., Iida, M., Orbuch, R. A., McDaniel, N. K., Nickel, K. P., Kimple, R. J., . . . Wheeler, D. L. (2018)., Overcoming resistance to cetuximab with honokiol, A small-molecule polyphenol., Molecular Cancer Therapeutics, 17(1), 204-214. doi:10.1158/1535-7163.MCT-17-0384 [doi]\n\nAl-Azayzih, A., Gao, F., & Somanath, P. R. (2015)., P21 activated kinase-1 mediates transforming growth factor beta1-induced prostate cancer cell epithelial to mesenchymal transition., Biochimica Et Biophysica Acta, 1853(5), 1229-1239. doi:10.1016/j.bbamcr.2015.02.023 [doi]\n\nLubik, A. A., Nouri, M., Truong, S., Ghaffari, M., Adomat, H. H., Corey, E., . . . Buttyan, R. (2017), Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment., International Journal of Cancer, 140(2), 358-369. doi:10.1002/ijc.30450 [doi]\n\nStaniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V., PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors, Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.\n\nGozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H., PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer Cell. 2021 Sep 13;39(9):1214-1226.e10. doi: 10.1016/j.ccell.2021.06.018. Epub 2021 Jul 22.\n\nYang A, Zhang Z, Chaurasiya S, Park AK, Lu J, Kim SI, Valencia H, Fong Y, Woo Y., Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases., Mol Ther Oncolytics. 2023 Oct 19;31:100734. doi: 10.1016/j.omto.2023.100734. eCollection 2023 Dec 19.\n\nStokes ME, Calvo V, Fujisawa S, Dudgeon C, Huang S, Ballal N, Shen L, Gasparek J, Betzenhauser M, Taylor SJ, Staschke KA, Rigby AC, Mulvihill MJ, Bose N, Lightcap ES, Surguladze D., PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors., Clin Cancer Res. 2023 Dec 1;29(23):4870-4882. doi: 10.1158/1078-0432.CCR-23-1182.\n\nKamiyama, H., Rauenzahn, S., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., . . . Eshleman, J. R. (2013)., Personalized chemotherapy profiling using cancer cell lines from selectable mice., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(5), 1139-1146. doi:10.1158/1078-0432.CCR-12-2127 [doi]\n\nZhang Z, Yang A, Chaurasiya S, Park AK, Kim SI, Lu J, Olafsen T, Warner SG, Fong Y, Woo Y., PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1, Mol Ther Oncolytics. 2021 Dec 31;24:331-339. doi: 10.1016/j.omto.2021.12.022. eCollection 2022 Mar 17.\n\nBerk C, Civenni G, Wang Y, Steuer C, Catapano CV, Hall J., Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo, Nucleic Acid Ther. 2021 Jun;31(3):237-244. doi: 10.1089/nat.2020.0852. Epub 2020 Apr 20.\n\nSteers GJ, O'Leary BR, Du J, Wagner BA, Carroll RS, Domann FE, Goswami PC, Buettner GR, Cullen JJ., Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer., Antioxidants (Basel). 2023 Aug 29;12(9). pii: 1683. doi: 10.3390/antiox12091683.\n\nCarroll RS, Du J, O'Leary BR, Steers G, Goswami PC, Buettner GR, Cullen JJ., Pharmacological ascorbate induces sustained mitochondrial dysfunction., Free Radic Biol Med. 2023 Aug 1;204:108-117. doi: 10.1016/j.freeradbiomed.2023.04.023. Epub 2023 May 1.\n\nAlexander, M. S., Wilkes, J. G., Schroeder, S. R., Buettner, G. R., Wagner, B. A., Du, J., . . . Cullen, J. J. (2018)., Pharmacological ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer., Cancer Research, doi:canres.1680.2018 [pii]\n\nLi X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D., Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer, Theranostics. 2021 May 8;11(14):6873-6890. doi: 10.7150/thno.49235. eCollection 2021.\n\nZhang, Y. J., Zhan, X., Wang, L., Ho, R. J., & "
    }
}